CPI-444 shows promise two ways
BURLINGAME, Calif.—Biopharmaceutical company Corvus Pharmaceuticals Inc. debuted encouraging preclinical data and preliminary biomarker data from its ongoing Phase 1/1b study of CPI-444 at this year’s CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival. The study is evaluating CPI-444, a potent and selective inhibitor of the adenosine A2A receptor, as a single agent and in combination with Genentech’s TECENTRIQ (atezolizumab), a fully humanized monoclonal antibody targeting PD-L1. As reported at the conference, CPI-444 has been found to be active as both a single agent and in combination with anti-PD-1 and anti-PD-L1 antibodies at stimulating immune cells, generating anti-tumor immunity, suppressing tumor growth, delaying tumor progression and generating total tumor rejection in animal models of cancer. CD8+ cytotoxic T lymphocytes have been found to be necessary for the compound’s activity, and animals previously treated with CPI-444 showed long-term immunity upon tumor re-challenge.